During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

In terms of response, it met its primary end point in all 3 doses. 1 The ORR was 50% or higher [in all 3 groups]. The dose of ...

Fintel reports that on March 18, 2025, Guggenheim downgraded their outlook for Incyte (NasdaqGS:INCY) from Buy to Neutral.

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Value investors believe that owning a stock is owning a slice of the underlying business… but this isn’t always true. ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...